Cochlear's Osia OSI300 Implant wins Innovator Award

November 3, 2023

Media Contact

Christy LaPlante
Public Relations Manager
Cochlear Americas

Cochlear's Osia OSI300 Implant wins Innovator Award

Lone Tree, CO (November 3, 2023) — Cochlear has been recognized for the new OSI300 Implant in the Cochlear™ Osia® System in the fourth annual Hearing Technology Innovator Awards™. The annual awards program by Hearing Health & Technology Matters (HHTM) acknowledges technological innovation and accomplishments in the hearing industry.

W3_CORRECTED_badge2023.png OSI300 5b_OSI300 transparent transducer for green BG_White SP_BI300 for green BG_Shadow.psd


Launched commercially in October 2023, the Osia® System with the new Osia OSI300 Implant is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery.1

The OSI300 Implant is specifically designed to support access to MRI with no performance degradation after MRI exposure2,3, as there is nothing to be demagnetized as in an electromagnetic transducer. Unlike an axial magnet, which is found in most bone conduction implants today and is unsuitable for a patient undergoing an MRI examination at 3.0 T, the OSI300 uses a diametric magnet that sits within a casing and rotates to align with the magnetic field of the MRI machine.

“We are humbled to be recognized for our new Osia System’s OSI300 Implant by the Hearing Technology Innovator Awards. We know that this innovation will make a difference in our recipients’ lives knowing that most people can expect to undergo an MRI scan at some point in their lifetime,” Ryan Lopez, Head of Portfolio Strategy & Professional Marketing at Cochlear, said.

"The Innovator Awards aim to acknowledge the individuals and organizations that transform groundbreaking hearing care concepts into reality and companies like Cochlear are playing a pivotal role in advancing innovation throughout the industry,” Dr. Robert Traynor, member of the 2023 Awards program judge's panel, said.

This year's program featured numerous innovative technologies submitted by companies from all around the world across eight distinct categories. Since 2020, the awards program has raised over $25,000 in support of hearing-related charities.

About Cochlear Limited (ASX: COH)

Cochlear is the global leader in implantable hearing solutions. The company has a global workforce of more than 4,000 people and invests more than AUD$180 million each year in research and development. Products include cochlear implants, bone conduction implants and acoustic implants, which healthcare professionals use to treat a range of moderate to profound types of hearing loss.

Since 1981, Cochlear has provided more than 700,000 implantable devices, helping people of all ages, in more than 180 countries, to hear.

About the Hearing Technology Innovator Awards

The Hearing Technology Innovator Awards™ is an international awards program designed to recognize and celebrate innovation within the hearing industry. Since its inception, the program has helped raise over $25,000 for hearing charities. Learn more at

About HHTM

Hearing Health & Technology Matters (HHTM) provides timely information and lively insights to anyone who cares about hearing loss. Readers and contributors are drawn from many sectors of the hearing field, including practitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them. By involving all these groups, we hope to bridge the gaps in knowledge that so often divide them. To learn more, visit


For further information, please contact:

Christy LaPlante
Public Relations Manager


  1. Ellsperman SE, Nairn EM, Stucken EZ. Review of Bone Conduction Hearing Devices. Audiol Res. 2021;11(2):207-219.
  2. Technical Brief – Reliability: Cochlear™ Osia® OSI300 Implant . D1991745. October, Cochlear Limited 2023.
  3. Cochlear™ Osia® Magnetic Resonance Imaging (MRI) Guidelines. D1906375. August, Cochlear Limited 2023.